NeuroVoices: Shazam Hussain, MD, FRCP, FAHA, on Ultra-Early IV tPA to Treat Emergent LVO
August 25th 2021The director of the Cerebrovascular Center at Cleveland Clinic provided context on why stroke systems should incorporate IV tPA as early as possible to treat emergent large vessel occlusion.
nSight Platform for Remote Seizure Burden, Activity Tracking: Martha Morrell, MD
August 24th 2021Discussing the new platform, the chief medical officer of NeuroPace spoke on the potential to open and streamline patient-provider communication with the company’s nSight Platform and its RNS system.
ADVANCE Study Results Demonstrate Atogepant’s Potential for Migraine Prevention
August 24th 2021For the primary end point, the 3 dose options atogepant (AbbVie) were associated with a reduction ranging from 3.9 to 4.2 days in the mean number of headache days per month for those with episodic migraine.
Highlights of AASM Guideline for Treatment of Central Disorders of Hypersomnolence
August 24th 2021Coauthor and member of the American Academy of Sleep Medicine board of directors, Lynn Marie Trotti, MD, MSc, discussed key takeaways from the new guideline, which encompasses the first updates since 2007.
Recent Breakthroughs in the Treatment of Alzheimer Disease
August 23rd 2021This NeurologyLive® Peers & Perspectives series features experts in the diagnosis and treatment of Alzheimer disease discussing the recent approval of aducanumab, its implications for Alzheimer disease, and other promising therapies and diagnostic technologies in development.
Detecting the Earliest Signs of Alzheimer Disease and Brain Amyloid Status
August 22nd 2021Michael Weiner, MD, professor of radiology and biomedical imaging, medicine, psychiatry, and neurology at the University of California–San Francisco, discussed the findings of a systematic review aimed at evaluating models that predict dichotomous Aß.
BTK Inhibitor Fenebrutinib Aims to Tackle Progressive MS in FENtrepid Trial
August 20th 2021The agent’s safety profile has been studied in more than 1200 individuals to date across several inflammatory diseases, with data indicating that the high selectivity of fenebrutinib may limit off-target effects.
Miniature Brain Model Aims to Reduce Cost, Accelerate Drug Discovery for Alzheimer Disease
August 20th 2021Yanhong Shi, PhD, director, stem cell biology research, City of Hope National Medical Center, discussed the potential of a new brain organoid model, which was developed to study sporadic Alzheimer disease.